Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630796 | 0.99 | SLC6A3 (0.37) | SLC6A3SLC6A4HDAC4MAOBMAOA | |
| SCHEMBL10042119 | 0.96 | HDAC4 (0.35) | SLC6A3SLC6A4HDAC4MAOBMAOA | |
| SCHEMBL1632006 | 0.88 | HDAC4 (0.42) | SLC6A3SLC6A4HDAC4MAOBMAOA | |
| SCHEMBL15436406 | 0.88 | HDAC4 (0.38) | SLC6A3SLC6A4HDAC4 | |
| SCHEMBL401435 | 0.88 | HDAC4 (0.38) | SLC6A3SLC6A4HDAC4 | |
| SCHEMBL440243 | 0.86 | ESR1 (0.39) | SLC6A3SLC6A4HDAC4 | |
| SCHEMBL1629501 | 0.83 | SLC6A3 (0.38) | SLC6A3SLC6A4HDAC4OPRM1 | |
| SCHEMBL1688019 | 0.81 | MEN1 (0.47) | SLC6A3SLC6A4 | |
| SCHEMBL1688040 | 0.80 | MEN1 (0.46) | SLC6A3SLC6A4 | |
| SCHEMBL399556 | 0.78 | RORC (0.45) | SLC6A3MAOBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470872-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | SLC6A3 1425/4885SLC6A4 1641/4885HDAC4 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.